Clinical bottom line
Adipose tissue macrophage polarization, shifting between pro-inflammatory (M1) and anti-inflammatory (M2) states, plays a pivotal role in the pathogenesis of insulin resistance and type 2 diabetes (T2D). Emerging therapies targeting this polarization to promote M2 phenotypes show promise in reducing adipose tissue inflammation and improving insulin sensitivity. While preclinical and early translational studies suggest potential benefits, clinical evidence remains limited. These approaches warrant further validation before integration into routine diabetes management but represent a novel immunometabolic target that may complement existing therapies.
What the evidence shows
Obesity-induced adipose tissue inflammation is a key driver of insulin resistance, with macrophages as central mediators (Hsieh et al., 2011). In obese adipose tissue, macrophages predominantly adopt a pro-inflammatory M1 phenotype, secreting cytokines that impair insulin signaling. Conversely, M2 macrophages exert anti-inflammatory effects that support insulin sensitivity.
Recent mechanistic studies highlight molecular pathways regulating macrophage polarization. Xu et al. (2023) demonstrated that PSTPIP2 promotes M2 polarization via activation of PPARγ, alleviating adipose tissue inflammation and improving insulin resistance in diabetic mice. Conversely, Zhang et al. (2016) showed that miR-130b suppresses PPARγ, reducing M2 polarization and exacerbating inflammation and insulin resistance.
A novel peptide targeting SVEP1, a protein implicated in adipose tissue macrophage activation, was shown by Kislev et al. (2024) to suppress macrophage-induced inflammation and mitigate insulin resistance in obesity models, suggesting therapeutic potential.
Additional modulators include adiponectin, which Weng et al. (2026) found to improve insulin resistance by modulating macrophage polarization in visceral adipose tissue under chronic intermittent hypoxia, a condition relevant to obstructive sleep apnea often comorbid with T2D.
These findings collectively support the hypothesis that shifting macrophage polarization toward an M2 phenotype may reduce adipose tissue inflammation and improve metabolic outcomes in T2D.
Caveats and uncertainty
Most evidence derives from animal models or in vitro studies; human clinical data are sparse. The complexity of macrophage phenotypes and their plasticity in vivo complicates therapeutic targeting. The safety and efficacy of agents modulating macrophage polarization remain to be established in well-powered clinical trials.
Heterogeneity in patient populations, obesity phenotypes, and comorbidities may influence response to such therapies. Additionally, macrophage polarization is only one aspect of adipose tissue dysfunction; other immune cells and metabolic pathways also contribute to insulin resistance.
The long-term consequences of altering immune cell phenotypes are unknown, including potential impacts on host defense and tissue homeostasis.
How this may change practice
If validated in clinical trials, therapies targeting adipose tissue macrophage polarization could complement existing antidiabetic agents by addressing underlying inflammation and immune dysregulation in obesity-related insulin resistance.
Such treatments might be particularly relevant for patients with obesity-driven T2D who exhibit persistent inflammation despite standard glycemic control. Biomarkers of macrophage activation or polarization states could aid patient selection and monitoring.
Integration into practice would require careful assessment of safety, dosing, and combination with current therapies such as metformin or GLP-1 receptor agonists.
For now, clinicians should remain aware of this emerging area as a potential future avenue for immunometabolic intervention in T2D management.